Navigation Links
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Date:6/8/2009

," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 4, 2015 ... cible les épidémies que sont l,hypertension, le diabète ... du Sud-Est, par l,intermédiaire de plateformes éducatives gratuites ...      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) ... charge le diabète en ligne , Prendre ...
(Date:7/3/2015)... July 3, 2015 Un ... épidémies que sont l,hypertension, le diabète et les ... plateformes éducatives gratuites et d,une conférence majeure dédiée ... http://photos.prnewswire.com/prnh/20150630/227033 ) , Les formations ... , Prendre en charge l,hypertension en ligne ...
(Date:7/3/2015)... , July 3, 2015  Obsidian HDS, the developer ... online service for the management of data on pharmaceutical ... that PharmaShine now includes the 2014 Open Payments General ... Services on June 30. The data disclosed on Open ... between industry and providers totaling $6.49 billion and is ...
Breaking Medicine Technology:Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Cincinnati Children,s Hospital Medical Center collaborated on a 14-month ... management of teenagers with Asthma. "Mobile ... bridging knowledge to action in adolescents but there was ... as a basis for efforts to secure funding for ...
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) today ... Vice President of Research and Development, Cynthia Schwalm as ... as Senior Vice President of Pharmacovigilance. These newly created ... Company prepares for the potential launch of its lead ...
Cached Medicine Technology:GenerationOne Selected by Cincinnati Children's Hospital Medical Center for Mobile Health Pilot with Teen Asthmatics 2GenerationOne Selected by Cincinnati Children's Hospital Medical Center for Mobile Health Pilot with Teen Asthmatics 3Optimer Pharmaceuticals Expands Senior Management Team 2Optimer Pharmaceuticals Expands Senior Management Team 3Optimer Pharmaceuticals Expands Senior Management Team 4Optimer Pharmaceuticals Expands Senior Management Team 5
(Date:7/3/2015)... ... ... Bank will hopefully be getting a large donation of canned food items at the ... are making it their mission to collect as many canned items as possible. Donations do ... public as well. As part of the canned food drive, these local chiropractors will be ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... and speaker lineup for its 2015 Annual Conference , the premiere ... 2015 at the Renaissance Orlando at SeaWorld in Orlando, Florida. Speakers include ...
(Date:7/3/2015)... Kan. (PRWEB) , ... July 03, 2015 , ... ... dedicated exclusively to healthcare providers, has been retained to lead a national ... top-ranked executive search firms in the healthcare industry, B. E. Smith has recently ...
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the ... good blender and easily accessible, quality ingredients. Aurora Natural is proud to introduce a ... added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering a ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the ... Manzanares, MD as the new Medical Director of its Frisco facility. , “We are ... Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3
... Customers Come From?, Enables Public To Give And ... ... Do Customers Come,From?, the new Internet marketing book by successful New Jersey,entrepreneur ... for its timely content and the author,s generous charitable campaign,Billy Gives Back,. ...
... STAAR Surgical,Company (Nasdaq: STAA ) today announced ... quarter ended September 29, 2007 on Tuesday, October,30, ... host a conference call,and webcast on Tuesday, October ... the Company,s third quarter and current corporate developments. ...
... . , A team of researchers from the ... University of Murcia, has developed a visual aid device ... especially those suffering from pathologies with a slow progression ... Degeneration, cataracts, etc.). This platform, called SERBA (in Spanish, ...
... as breakbone fever because of the excruciating back and joint ... health threat for people living in tropical countries, as well ... Rico, according to research being presented at the annual meeting ... Nov. 4-7. , Protocol Needed to Screen Blood ...
... FRESNO, Calif., Oct. 16 Almost 40% of ... food supply has,decreased over the past twelve months, according ... The registered dieticians and nutritionists also indicated a strong,preference ... with a,choice, they prefer food that was produced in ...
... Herley Industries,Inc. (Nasdaq: HRLY ) announced ... has been awarded a contract valued at,approximately $5 ... will produce high power amplifiers for EDO,s CVRJ ... and CEO, commented, "EDO has recently,announced awards with ...
Cached Medicine News:Health News:New Jersey Entrepreneur Turns a Page for Four National Charities 2Health News:STAAR Surgical Announces Third Quarter 2007 Earnings Release Date and Conference Call 2Health News:Computer simulator allows visually-impaired to drive 2Health News:Computer simulator allows visually-impaired to drive 3Health News:Substantial costs and underreporting of dengue fever, concerns about blood supply face US 2Health News:Dieticians & Nutritionists Report Decreased Confidence in Food Supply 2Health News:Herley Industries, Inc. Receives a $5 Million Award from EDO for Electronic Components for IEDs 2
... The Gemini is the newest addition ... With two distinct wavelengths to choose from, ... stands out in an exploding non-invasive aesthetic ... versatility, speed and effectiveness while maintaining the ...
... The 800 Series KTP/YAG™ Surgical Laser ... market. It is a high-power, dual-wavelength ... plastic surgery, orthopedics, general surgery, neurosurgery, ... KTP/532™ beam surgically cuts, vaporizes and ...
... D 980 nm diode laser provides controlled ... for most surgical procedures. Unlike other ... without collateral tissue damage or charring. ... instantly and seals small blood vessels ...
... a monoclonal antibody based coagglutination ... identification of Neisseria gonorrhoeae. The ... viable or fresh cultures. After ... minute rotation, a positive reaction ...
Medicine Products: